Novel Modulators of GABABR1a
AssigneesVib Vzw, Katholieke Universiteit Leuven, Vrije Universiteit Brussel
InventorsJoris De Wit, Ana Rita Santos, Joao Carvalho, Laurent Galibert, Inge Van Molle, Han Remaut, Sylvain Celanire
Life of this patent
Estimating the term…
Abstract
The present invention relates to the field of disorders of the central and peripheral nervous system, in particular neurological and psychiatric disorders, and the prevention and/or treatment thereof. In particular, the present invention relates to the finding that short peptides derived from the soluble amyloid precursor protein α (sAPPα) bind and modulate GABABR1a. The peptides are provided for clinical use, more particularly for the treatment of neurological diseases such as CMT as well as for psychiatric disorders.
Claims8
A GABABR1a binding peptide comprising the sequence X1X2X3X4X5, wherein
- X1 is D, N, G, P or S;
- X2 is V or I;
- X3 is W, F, Y or H;
- X4 is W or Y;
- and
- X5 is G or S,
- or a peptidomimetic thereof, wherein the GABABR1a binding peptide or peptidomimetic thereof has a length of between 5 and 17 amino acids and wherein the GABABR1a binding peptide or peptidomimetic thereof does not comprise DDSDVWWGG.
(canceled)
Dependencies are inferred from the claim text.